Rezolute, Inc. (RZLT)
Largest Insider Buys in Sector
RZLT Stock Price History Chart
RZLT Stock Performance
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Activity of Rezolute, Inc.
Over the last 12 months, insiders at Rezolute, Inc. have bought $544,888 and sold $0 worth of Rezolute, Inc. stock.
On average, over the past 5 years, insiders at Rezolute, Inc. have bought $8.36M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Evans Daron (CFO) — $1.09M. ROBERTS BRIAN KENNETH (Chief Medical Officer) — $103,062. Kim Young-Jin (director) — $69,859.
The last purchase of 7,600 shares for transaction amount of $29,743 was made by ROBERTS BRIAN KENNETH (Chief Medical Officer) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Rezolute, Inc.
| 2024-06-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 7,600 0.0139% | $3.91 | $29,743 | -1.90% | ||
| 2024-06-14 | Evans Daron | CFO | 40,000 0.0754% | $4.04 | $161,568 | -1.90% | ||
| 2024-05-29 | Evans Daron | CFO | 451 0.001% | $3.50 | $1,579 | +1.69% | ||
| 2024-05-24 | Evans Daron | CFO | 2,942 0.0077% | $3.23 | $9,503 | +16.15% | ||
| 2024-05-23 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 7,500 0.0164% | $2.69 | $20,138 | +35.41% | ||
| 2024-05-23 | Evans Daron | CFO | 58 0.0001% | $2.85 | $165 | +35.41% | ||
| 2024-03-28 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 500 0.0013% | $2.55 | $1,275 | +18.63% | ||
| 2024-03-15 | Evans Daron | CFO | 20,000 0.048% | $1.69 | $33,830 | +62.92% | ||
| 2024-03-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 10,000 0.024% | $1.88 | $18,800 | +59.07% | ||
| 2024-03-08 | Evans Daron | CFO | 50,000 0.1293% | $1.93 | $96,345 | +50.00% | ||
| 2024-03-07 | Kim Young-Jin | director | 36,503 0.0963% | $1.91 | $69,859 | +56.91% | ||
| 2024-03-07 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 500 0.0013% | $1.85 | $925 | +56.91% | ||
| 2024-02-26 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 2,000 0.0052% | $1.70 | $3,400 | +70.12% | ||
| 2024-02-26 | Elam Nevan C | CEO | 5,000 0.0129% | $1.68 | $8,400 | +70.12% | ||
| 2024-02-23 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 6,000 0.015% | $1.69 | $10,140 | +59.59% | ||
| 2024-02-16 | Evans Daron | CFO | 46,400 0.1132% | $1.31 | $60,576 | +97.78% | ||
| 2024-02-16 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 7,000 0.0171% | $1.31 | $9,142 | +97.78% | ||
| 2023-07-03 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 5,000 0.0091% | $1.90 | $9,500 | -27.90% | ||
| 2022-07-22 | HANDOK, INC. | 3.16M 7.7108% | $3.80 | $12M | ||||
| 2022-07-22 | Kim Young-Jin | director | 78,947 0.1928% | $3.80 | $299,999 |
Insider Historical Profitability
| Kim Young-Jin | director | 115450 0.2914% | $4.00 | 2 | 0 | |
| Evans Daron | CFO | 40000 0.1789% | $4.00 | 7 | 0 | |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 54352 0.0695% | $4.00 | 11 | 0 | <0.0001% |
| Elam Nevan C | CEO | 7817 0.0197% | $4.00 | 1 | 0 | |
| Genexine Inc. | 10 percent owner | 91300933 230.4107% | $4.00 | 1 | 0 | |
| HANDOK, INC. | 10 percent owner | 5942617 5.0864% | $4.00 | 72 | 0 | <0.0001% |
| Welch David F | director | 1811415 4.5714% | $4.00 | 13 | 0 | |
| CHU JUE MIN | 10 percent owner | 893750 2.2555% | $4.00 | 1 | 0 | |
| Labrucherie Gil M | director | 53572 0.1352% | $4.00 | 1 | 0 | <0.0001% |
| Hogenhuis Wladimir | director | 32693 0.0825% | $4.00 | 2 | 0 | <0.0001% |
| BAR NIR | President and Treasurer | 0 0% | $4.00 | 1 | 1 | |
| WOLKIN ORIT | 10 percent owner | 0 0% | $4.00 | 1 | 1 | |
| TURNOWSKI GUY | Secretary | 0 0% | $4.00 | 0 | 1 | |
| KAEYO INVESTMENTS LTD | 10 percent owner | 0 0% | $4.00 | 1 | 1 |
Institutional Investor Ownership
| Federated Hermes | $25.89M | 25.3 | 10.15M | 0% | +$0 | 0.06 | |
| Nantahala Capital Management Llc | $7.71M | 7.53 | 3.02M | +96.59% | +$3.79M | 0.79 | |
| Vivo Capital | $7.13M | 6.97 | 2.8M | -13.73% | -$1.14M | 0.63 | |
| Affinity Asset Advisors | $4.08M | 3.99 | 1.6M | New | +$4.08M | 0.73 | |
| The Vanguard Group | $3.96M | 3.87 | 1.55M | +10.35% | +$371,535.04 | <0.0001 | |
| Blackstone | $3.92M | 3.83 | 1.54M | 0% | +$0 | 0.02 | |
| Caxton Corp | $3.36M | 3.29 | 1.32M | 0% | +$0 | 19.5 | |
| Sphera Fund | $2.54M | 2.48 | 996,710 | 0% | +$0 | 0.42 | |
| Adage Capital Partners Gp L L C | $1.61M | 1.57 | 631,690 | 0% | +$0 | <0.01 | |
| Ubs Oconnor Llc | $1.6M | 1.56 | 626,259 | +4.16% | +$63,749.98 | 0.14 | |
| Velan Capital | $1.02M | 1 | 400,000 | New | +$1.02M | 0.56 | |
| Citadel Advisors LLC | $1.02M | 0.99 | 398,423 | +14.97% | +$132,278.75 | <0.01 | |
| BlackRock | $905,035.00 | 0.88 | 354,916 | +35.4% | +$236,627.04 | <0.0001 | |
| Geode Capital Management | $860,037.00 | 0.84 | 337,190 | +28.38% | +$190,124.32 | <0.0001 | |
| Renaissance Technologies | $842,000.00 | 0.82 | 330,081 | +542.11% | +$710,869.00 | <0.01 | |
| Bvf Inc Il | $486,578.00 | 0.48 | 190,815 | 0% | +$0 | <0.01 | |
| Silverarc Capital Management Llc | $387,562.00 | 0.38 | 151,985 | -3.25% | -$13,005.01 | 0.11 | |
| Stonepine Capital Management Llc | $309,771.00 | 0.3 | 121,479 | -95.61% | -$6.75M | 0.25 | |
| Acadian Asset Management | $229,000.00 | 0.23 | 90,346 | New | +$229,000.00 | <0.01 | |
| Northern Trust | $171,426.00 | 0.17 | 67,226 | -19.96% | -$42,737.93 | <0.0001 | |
| State Street | $151,909.00 | 0.15 | 59,572 | 0% | +$0 | <0.0001 | |
| Millennium Management LLC | $53,331.00 | 0.05 | 20,914 | +14.79% | +$6,872.29 | <0.0001 | |
| Virtu Financial Llc | $37,000.00 | 0.04 | 14,410 | New | +$37,000.00 | <0.01 | |
| Charles Schwab | $35,080.00 | 0.03 | 13,757 | 0% | +$0 | <0.0001 | |
| Boothbay Fund Management LLC | $30,600.00 | 0.03 | 12,000 | 0% | +$0 | <0.01 | |
| Cubist Systematic Strategies | $29,682.00 | 0.03 | 11,640 | New | +$29,682.00 | <0.0001 | |
| Xtx Topco Ltd | $28,078.00 | 0.03 | 11,011 | New | +$28,078.00 | <0.01 | |
| Ameritas Advisory Services Llc | $29,700.00 | 0.03 | 10,000 | New | +$29,700.00 | <0.01 | |
| Tower Research Capital | $12,459.00 | 0.01 | 4,886 | -56.9% | -$16,444.55 | <0.0001 | |
| Morgan Stanley | $5,281.00 | 0.01 | 2,071 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $655.00 | <0.01 | 257 | +9.36% | +$56.07 | <0.0001 | |
| Qube Research & Technologies | $5.00 | <0.01 | 2 | 0% | +$0 | <0.0001 |